143 related articles for article (PubMed ID: 15863156)
1. CA-125 AUC as a new prognostic factor for patients with ovarian cancer.
Mano A; Falcão A; Godinho I; Santos J; Leitão F; Oliveira C; Caramona M
Gynecol Oncol; 2005 May; 97(2):529-34. PubMed ID: 15863156
[TBL] [Abstract][Full Text] [Related]
2. [Prognostic value of early normalization of CA 125 during chemotherapy in stages III and IV ovarian tumors].
Ferrero JM; Largillier R; Ramaioli A; Heudier P; Teissier E; Namer M
Bull Cancer; 1997 Jul; 84(7):722-8. PubMed ID: 9339198
[TBL] [Abstract][Full Text] [Related]
3. Serum CA-125 level after 6 cycles of primary adjuvant chemotherapy is a useful prognostic factor for complete responders' survival in patients with advanced epithelial ovarian cancer.
Kim HS; Park NH; Chung HH; Kim JW; Song YS; Kang SB
Onkologie; 2008 Jun; 31(6):315-20. PubMed ID: 18547972
[TBL] [Abstract][Full Text] [Related]
4. CA125 level as a predictor of progression-free survival and overall survival in ovarian cancer patients with surgically defined disease status prior to the initiation of intraperitoneal consolidation therapy.
Juretzka MM; Barakat RR; Chi DS; Iasonos A; Dupont J; Abu-Rustum NR; Poynor EA; Aghajanian C; Spriggs D; Hensley ML; Sabbatini P
Gynecol Oncol; 2007 Jan; 104(1):176-80. PubMed ID: 16996584
[TBL] [Abstract][Full Text] [Related]
5. Prognostic significance of CA 125 and TPS levels after 3 chemotherapy courses in ovarian cancer patients.
van Dalen A; Favier J; Burges A; Hasholzner U; de Bruijn HW; Dobler-Girdziunaite D; Dombi VH; Fink D; Giai M; McGing P; Harlozinska A; Kainz C; Markowska J; Molina R; Sturgeon C; Bowman A; Einarsson R
Gynecol Oncol; 2000 Dec; 79(3):444-50. PubMed ID: 11104617
[TBL] [Abstract][Full Text] [Related]
6. Prognostic value of Ca 125 levels during primary therapy.
Markmann S; Gerber B; Briese V
Anticancer Res; 2007; 27(4A):1837-9. PubMed ID: 17649781
[TBL] [Abstract][Full Text] [Related]
7. Serum tumour marker CA 125 in monitoring of ovarian cancer during first-line chemotherapy.
Tuxen MK; Sölétormos G; Dombernowsky P
Br J Cancer; 2001 May; 84(10):1301-7. PubMed ID: 11355938
[TBL] [Abstract][Full Text] [Related]
8. Serum half-life of CA 125 during early chemotherapy as an independent prognostic variable for patients with advanced epithelial ovarian cancer: results of a multicentric Italian study.
Gadducci A; Zola P; Landoni F; Maggino T; Sartori E; Bergamino T; Cristofani R
Gynecol Oncol; 1995 Jul; 58(1):42-7. PubMed ID: 7789889
[TBL] [Abstract][Full Text] [Related]
9. Significance of preoperative serum CA-125 levels in the prediction of lymph node metastasis in epithelial ovarian cancer.
Kim HS; Park NH; Chung HH; Kim JW; Song YS; Kang SB
Acta Obstet Gynecol Scand; 2008; 87(11):1136-42. PubMed ID: 18951217
[TBL] [Abstract][Full Text] [Related]
10. Prognostic significance of CA 125 and TPS levels after chemotherapy in ovarian cancer patients.
van Dalen A; Favier J; Baumgartner L; Hasholzner U; de Bruijn H; Dobbler D; Dombi VH; Fink D; Giai M; McGing P; Harlozinska A; Kainz C; Markowska J; Molina R; Sturgeon C; Einarsson R
Anticancer Res; 1999; 19(4A):2523-6. PubMed ID: 10470187
[TBL] [Abstract][Full Text] [Related]
11. A retrospective study of preoperative CA 125 levels in 82 patients with ovarian cancer.
Rossi AC; Di Vagno G; Cormio G; Cazzolla A; Stefanelli S; D'Elia E; Selvaggi L
Arch Gynecol Obstet; 2004 May; 269(4):263-5. PubMed ID: 14745561
[TBL] [Abstract][Full Text] [Related]
12. Significance of early changes in the serum CA-125 antigen level on overall survival in advanced ovarian cancer.
Markman M; Federico M; Liu PY; Hannigan E; Alberts D
Gynecol Oncol; 2006 Oct; 103(1):195-8. PubMed ID: 16595148
[TBL] [Abstract][Full Text] [Related]
13. Value of serum CA125 levels in patients with high-risk, early stage epithelial ovarian cancer.
Kang WD; Choi HS; Kim SM
Gynecol Oncol; 2010 Jan; 116(1):57-60. PubMed ID: 19818996
[TBL] [Abstract][Full Text] [Related]
14. Monitoring cancer antigen 125 levels in induction chemotherapy for epithelial ovarian carcinoma and predicting outcome of second-look procedure.
Folk JJ; Botsford M; Musa AG
Gynecol Oncol; 1995 May; 57(2):178-82. PubMed ID: 7729730
[TBL] [Abstract][Full Text] [Related]
15. Factors associated with cytoreducibility among women with ovarian carcinoma.
Eltabbakh GH; Mount SL; Beatty B; Simmons-Arnold L; Cooper K; Morgan A
Gynecol Oncol; 2004 Nov; 95(2):377-83. PubMed ID: 15491760
[TBL] [Abstract][Full Text] [Related]
16. [Value of serum CA(125) detection for predicting recurrence and prognosis in ovarian epithelial cancer].
Wang XY; Ye J; Feng SW; Lü WG; Wan XY; Xie X
Zhonghua Fu Chan Ke Za Zhi; 2010 Nov; 45(11):813-6. PubMed ID: 21211277
[TBL] [Abstract][Full Text] [Related]
17. A new prognostic model for FIGO stage 1 epithelial ovarian cancer.
Obermair A; Fuller A; Lopez-Varela E; van Gorp T; Vergote I; Eaton L; Fowler J; Quinn M; Hammond I; Marsden D; Proietto A; Carter J; Davy M; Tripcony L; Abu-Rustum N
Gynecol Oncol; 2007 Mar; 104(3):607-11. PubMed ID: 17092548
[TBL] [Abstract][Full Text] [Related]
18. The prognostic value of pre-operative serum tetranectin, CA-125 and a combined index in women with primary ovarian cancer.
Høgdall CK; Nørgaard-Pedersen B; Mogensen O
Anticancer Res; 2002; 22(3):1765-8. PubMed ID: 12168866
[TBL] [Abstract][Full Text] [Related]
19. The value of serum and tissular expression of CA 125 antigen, in evaluation of the response to second line chemotherapy for the relapsed ovarian carcinoma.
Bădulescu F; Bădulescu A; Schenker M; Popescu CF; Stoica Z
Rom J Morphol Embryol; 2005; 46(4):329-34. PubMed ID: 16688372
[TBL] [Abstract][Full Text] [Related]
20. COX-2 and preoperative CA-125 level are strongly correlated with survival and clinical responsiveness to chemotherapy in ovarian cancer.
Raspollini MR; Amunni G; Villanucci A; Boddi V; Taddei GL
Acta Obstet Gynecol Scand; 2006; 85(4):493-8. PubMed ID: 16612714
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]